Phebe Lotfy Abdel-Messeih1, Manal Mohamed Alkady1, Neveen Mostafa Nosseir1, Mohamed Said Tawfik2. 1. Egyptian Atomic Energy Authority (EAEA), National Centers for Radiation Research and Technology (NCRRT), Health Radiation Research Department, Clinical Pathology Unit, Egypt. 2. Egyptian Atomic Energy Authority (EAEA), National Centers for Radiation Research and Technology (NCRRT), Health Radiation Research Department, Internal Medicine Unit, Cairo, Egypt.
Abstract
BACKGROUND: CXC chemokine ligand 16 (CXCL16) is an inflammatory chemokine that mediates renal infiltration of macrophages and activated T cells. Aim: To investigate serum levels of CXCL16 in patients undergoing hemodialysis and their correlation with other inflammatory markers such as C-reactive protein (CRP) and intact parathyroid hormone (iPTH). METHODS: The study included 40 hemodialysis patients (22 males) and 40 age and gender-matched controls (24 males). Fasting blood sugar (FBS), urea, creatinine, calcium and inorganic phosphorous were assayed in participants using routine methods, glycosylated hemoglobin (HbA1c) by quantitative chromatographic spectrophotometry, iPTH by chemiluminescent microparticle immunoassay, CRP by nephelometry and CXCL16 by ELISA technique. RESULTS: Serum CXCL16, CRP, PTH, FBS, HbA1c, phosphorus, urea, and creatinine levels were significantly higher in hemodialysis patients compared to controls (p<0.00001). No statistically significant differences were observed between patients and controls for calcium. Serum CXCL16 levels correlated positively with CRP (r=0.956, p<0.00001) and iPTH (r=-0.403, p<0.001). Hemodialysis patients (diabetics or hypertensives) had significantly higher CXCL16 levels compared to non-diabetics or non-hypertensives. CONCLUSIONS: High levels of serum CXCL16, CRP and iPTH reflect the inflammatory status of hemodialysis patients and help avoid complications. Serum CXCL16 could be used as a biomarker together with CRP in these patients. 2020 Phebe Lotfy Abdel-Messeih, Manal Mohamed Alkady, Neveen Mostafa Nosseir, Mohamed Said Tawfik, published by CEON/CEES.
BACKGROUND: CXC chemokine ligand 16 (CXCL16) is an inflammatory chemokine that mediates renal infiltration of macrophages and activated T cells. Aim: To investigate serum levels of CXCL16 in patients undergoing hemodialysis and their correlation with other inflammatory markers such as C-reactive protein (CRP) and intact parathyroid hormone (iPTH). METHODS: The study included 40 hemodialysis patients (22 males) and 40 age and gender-matched controls (24 males). Fasting blood sugar (FBS), urea, creatinine, calcium and inorganic phosphorous were assayed in participants using routine methods, glycosylated hemoglobin (HbA1c) by quantitative chromatographic spectrophotometry, iPTH by chemiluminescent microparticle immunoassay, CRP by nephelometry and CXCL16 by ELISA technique. RESULTS: Serum CXCL16, CRP, PTH, FBS, HbA1c, phosphorus, urea, and creatinine levels were significantly higher in hemodialysis patients compared to controls (p<0.00001). No statistically significant differences were observed between patients and controls for calcium. Serum CXCL16 levels correlated positively with CRP (r=0.956, p<0.00001) and iPTH (r=-0.403, p<0.001). Hemodialysis patients (diabetics or hypertensives) had significantly higher CXCL16 levels compared to non-diabetics or non-hypertensives. CONCLUSIONS: High levels of serum CXCL16, CRP and iPTH reflect the inflammatory status of hemodialysis patients and help avoid complications. Serum CXCL16 could be used as a biomarker together with CRP in these patients. 2020 Phebe Lotfy Abdel-Messeih, Manal Mohamed Alkady, Neveen Mostafa Nosseir, Mohamed Said Tawfik, published by CEON/CEES.
Authors: Alberto Ortiz; Adrian Covic; Danilo Fliser; Denis Fouque; David Goldsmith; Mehmet Kanbay; Francesca Mallamaci; Ziad A Massy; Patrick Rossignol; Raymond Vanholder; Andrzej Wiecek; Carmine Zoccali; Gérard M London Journal: Lancet Date: 2014-05-24 Impact factor: 79.321
Authors: M A Mitnick; A Grey; U Masiukiewicz; M Bartkiewicz; L Rios-Velez; S Friedman; L Xu; M C Horowitz; K Insogna Journal: Am J Physiol Endocrinol Metab Date: 2001-03 Impact factor: 4.310
Authors: Ze Bo Hu; Yan Chen; Yu Xiang Gong; Min Gao; Yang Zhang; Gui Hua Wang; Ri Ning Tang; Hong Liu; Bi Cheng Liu; Kun Ling Ma Journal: Int J Med Sci Date: 2016-10-20 Impact factor: 3.738
Authors: Mahmoud M Zakaria; Safaa A Derbala; Ayman E Salem; Amgad E El-Agroudy; Fatma M El-Tantawy Journal: Mol Biol Rep Date: 2021-09-01 Impact factor: 2.316
Authors: Fatma M El-Senosy; Rasha Elsayed Mohamed Abd El Aziz; Sammar Ahmed Kasim; Lamia Abdulbary Gad; Donia Ahmed Hassan; Seham Sabry; Ismail Mohamed El Mancy; Taiseer Ahmed Shawky; Ibrahim Ghounim Ramadan Mohamed; Rady Elmonier; Essam Kotb; Abeer Mohammed Abdul-Mohymen Journal: Int J Clin Pract Date: 2022-07-13 Impact factor: 3.149